Fatal cerebral hemorrhage associated with cyclosporin-A/FK506-related encephalopathy after allogeneic bone marrow transplantation

Mori, A.; Tanaka, J.; Kobayashi, S.; Hashino, S.; Yamamoto, Y.; Ota, S.; Asaka, M.; Imamura, M.
October 2000
Annals of Hematology;Oct2000, Vol. 79 Issue 10, p588
Academic Journal
We report a case of cerebral hemorrhage associated with cyclosporin A (CsA)/FK506-related encephalopathy that developed in a 16-year-old woman after allogeneic bone marrow transplantation. Hematopoietic engraftment occurred on day 15, and the patient developed systemic convulsions after CsA was replaced by FK506 for the treatment of acute graft-versus-host disease (GVHD). Based on magnetic resonance imaging, laboratory findings and cerebrospinal fluid studies, she was diagnosed as having CsA/FK506-related encephalopathy with cerebral hemorrhagic infarction. Although she recovered completely after discontinuation of FK506, she developed convulsions again 15 days after re-administration of FK506. A computed tomography scan showed cerebral hemorrhage. She died of respiratory failure. Vascular damage induced by immunosuppressive drugs and enhanced by acute GVHD seemed to be the cause of the cerebral hemorrhage. Since hypertension, which was present during both of the central nervous system events, seemed to have contributed to the development of the cerebral hemorrhage, it is proposed that CsA and FK506 should be reduced or discontinued when patients who have risk factors of hypertension become hypertensive even if they have no symptoms of neurotoxicity.


Related Articles

  • Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bleggi-Torres, L F; de Medeiros, B C; Werner, B; Neto, J Zanis; Loddo, G; Pasquini, R; de Medeiros, C R // Bone Marrow Transplantation;2/1/2000, Vol. 25 Issue 3, p301 

    We prospectively evaluated the neuropathological complications of 180 patients who underwent autopsy studies following bone marrow transplantation (BMT) (177 allogeneic, three autologous). The most frequent underlying disorders included severe aplastic anemia (n = 55), chronic myelogenous...

  • Bone marrow transplantation in severe Glanzmann’s thrombasthenia with antiplatelet alloimmunization. Bellucci, S; Damaj, G; Boval, B; Rocha, V; Devergie, A; Agha, I Yacoub; Garderet, L; Ribaud, P; Traineau, R; Socié, G; Gluckman, E // Bone Marrow Transplantation;2/1/2000, Vol. 25 Issue 3, p327 

    Glanzmann’s thrombasthenia is an autosomal recessive disorder characterized by a lack of platelet aggregation due to the absence of platelet glycoprotein IIb and IIIa. Usually, the disease leads to mild hemorrhage but sometimes bleeding is severe enough to be life-threatening. We report...

  • Pre-transplant risk factors for cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia after hematopoietic cell transplantation. Nakasone, H; Onizuka, M; Suzuki, N; Fujii, N; Taniguchi, S; Kakihana, K; Ogawa, H; Miyamura, K; Eto, T; Sakamaki, H; Yabe, H; Morishima, Y; Kato, K; Suzuki, R; Fukuda, T // Bone Marrow Transplantation;Oct2013, Vol. 48 Issue 10, p1368 

    A correction to the article "Bone Marrow Transplantation" that was published in the August 12, 2013 issue is presented.

  • Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Kobayashi, R; Watanabe, N; Iguchi, A; Cho, Y; Yoshida, M; Arioka, H; Naito, H; Shikano, T; Ishikawa, Y // Bone Marrow Transplantation;2/1/98, Vol. 21 Issue 3, p217 

    High-dose busulfan (BU) is widely used in combined chemotherapy before allogeneic or autologous bone marrow transplantation. Convulsions are reported as a side-effect of high-dose BU. We recorded electroencephalograms (EEGs) before and on the third day of BU administration in 22 patients....

  • Intravesical Instillation of Cidofovir in the Treatment of Hemorrhagic Cystitis Caused by Adenovirus Type 11 in a Bone Marrow Transplant Recipient. Fanourgiakis, Panagiotis; Georgala, Aspasia; Vekemans, Marc; Triffet, Agnes; De Bruyn, Jean-Marc; Duchateau, Valerie; Martiat, Philippe; De Clercq, Erik; Snoeck, Robert; Wollants, Elke; Rector, Annabel; Van Ranst, Marc; Aoun, Michael // Clinical Infectious Diseases;1/1/2005, Vol. 40 Issue 1, p199 

    Hemorrhagic cystitis that occurs late after bone marrow transplantation (BMT) in BMT recipients is often associated with adenovirus or polyomavirus BK infections intravesical instillation of cidofovir in a BMT recipient with intractable hemorrhagic cystitis resulted in clinical improvement....

  • Acute bleeding and thrombocytopenia after bone marrow transplantation. Nevo, S; Enger, C; Hartley, E; Borinsky, M E; Swan, V; Fuller, A K; Braine, H G; Kickler, T S; George, J N; Vogelsang, G B // Bone Marrow Transplantation;1/1/2001, Vol. 27 Issue 1, p65 

    The relationship between hemorrhage and low platelet count was first established in patients with acute leukemia, and has been widely applied to thrombocytopenic patients, including BMT patients. Yet, the role of thrombocytopenia in bleeding post BMT has not been systematically studied. We...

  • Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Blatt, J; Gold, S H; Wiley, J M; Monahan, P E; Cooper, H C; Harvey, D // Bone Marrow Transplantation;8/15/2001, Vol. 28 Issue 4, p405 

    Recombinant factor VIIa (rFVIIa, NovoSeven) is FDA-approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A growing literature suggests that there may be expanded indications for the use of NovoSeven in patients with significant bleeding who do not have a known...

  • Successfully treated invasive central nervous system aspergillosis in an allogeneic stem cell transplant recipient. Başlar, Z; Soysal, T; Hancı, M; Aygün, G; Ferhanoğlu, B; Sarioğlu, A Çetin; Ülkü, B // Bone Marrow Transplantation;8/15/98, Vol. 22 Issue 4, p404 

    Reports on a patient who underwent bone marrow transplantation and survived invasive aspergillosis of the central nervous system. Diagnosis of aplastic anemia with pancytopenia; Medical history of the patient; Treatment with fluconazole.

  • Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Tomonari, Akira; Iseki, Tohru; Takahashi, Satoshi; Ooi, Jun; Yamada, Toshiki; Takasugi, Kashiya; Nagamura, Fumitaka; Uchimaru, Kaoru; Tojo, Arinobu; Asano, Shigetaka // Annals of Hematology;Sep2004, Vol. 83 Issue 9, p573 

    We studied ganciclovir (GCV)-related neutropenia after preemptive therapy for cytomegalovirus infection: 9 of 17 (53%) cord blood transplantation (CBT) patients and 18 of 20 (90%) bone marrow transplantation (BMT) patients developed GCV-related neutropenia with an absolute neutrophil count (ANC)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics